Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2019-09-12 Regulatory Filings
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia och universitetssjukhus i världsklass slutför avtal om insamling av blodprov i bukspottkörtelcancer för IMMray® PanCan-d
Regulatory Filings Classification · 99% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a specific business development: an agreement with Beth Israel Deaconess Medical Center (BIDMC) to collect blood samples for the validation of the IMMray® PanCan-d test. It includes details about the next steps towards commercialization, timelines (e.g., Q4 2019, Q2 2020), and contact information for Investor Relations. This structure—a formal announcement of a material event or business update, often released under EU Market Abuse Regulation (MAR) as noted at the end—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement of a significant operational/partnership event, and it is not a specific financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for such announcements not covered by more specific codes like DIV, CAP, or MANG.
2019-09-12 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-June 2019. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance and research/development. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year. H1 2019
2019-08-23 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January-June 2019' and contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and key performance indicators for the specified period. It provides a detailed management discussion and analysis of the group's performance, research and development, and financing. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-23 English
Erlangen University Hospital and Immunovia enter into a collaboration agreement for the collection of pancreatic cancer blood samples for the final steps of IMMray™ PanCan-d development
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a collaboration agreement between Erlangen University Hospital and Immunovia regarding the collection of blood samples for the final development steps of a diagnostic test (IMMray™ PanCan-d). It includes forward-looking statements about commercialization timelines (yearend 2019, Q2 2020, Q3 2020) and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation. This structure—a brief announcement of a significant business event (collaboration, development progress) released via press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it details operational/development progress rather than just management changes (MANG) or insider trades (DIRS), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or RNS if it's a general market-moving announcement. Given the context of providing updates on development milestones and future readouts, it functions as a key operational update often bundled with or released near earnings. However, the most precise category for a general, market-moving announcement that isn't a specific financial report or management change is often RNS, but ER is used for key operational/financial highlights. Since this is a specific operational/development update, and not a formal earnings summary, RNS is the safest general regulatory announcement category, though ER is plausible if this was released concurrently with quarterly results. Given the lack of specific financial figures (revenue, profit, EPS), RNS (Regulatory Filings) is the most appropriate fallback for a significant, non-standard announcement.
2019-07-17 English
Erlangens universitetssjukhus och Immunovia ingår samarbetsavtal om insamling av blodprov vid bukspottkörtelcancer för de sista stegen i IMMray® PanCan-d utvecklingen
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated July 17, 2019. It announces a new collaboration agreement between Immunovia AB and Erlangen University Hospital regarding the collection of blood samples for the final stages of IMMray® PanCan-d development. The text explicitly mentions that the information is being made public according to EU market abuse regulation and provides contact details for Investor Relations. This structure—a formal announcement of a business development or operational update, often referencing previous releases and future timelines, but not being a full financial report (like 10-K or IR) or a transcript—strongly suggests a general regulatory announcement or press release. Since it details a specific operational/business development (a new partnership for sample collection) rather than a change in management (MANG), a dividend (DIV), or a capital event (CAP/SHA), and it is not a standard regulatory form like 10-K, the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially a specific type if one fits better. Given the content is a business development update, RNS (Regulatory Filings/Miscellaneous Announcement) is the best fit among the provided options, as it is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance document. It is a standard corporate announcement.
2019-07-17 Swedish
Resultat från optimeringsstudien IMMray™ PanCan-d presenteras på PancreasFest 2019
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated July 11, 2019. It announces that results from a study (IMMray™ PanCan-d) will be presented at an upcoming conference (PancreasFest 2019). It details key findings (ROC AUC values) and includes quotes from the CEO, contact information for Investor Relations, and a concluding statement indicating the information is disclosed under EU Market Abuse Regulation. This structure—a brief announcement highlighting key data points and referencing a future presentation or publication—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not the full financial report (10-K or IR) nor a transcript (CT), and it is a specific announcement of results/data presentation, it fits best as an Earnings Release (ER) if it were quarterly results, or a Regulatory Filing (RNS) for general news. Given the content is a scientific/clinical data update rather than standard quarterly financial performance highlights, and it explicitly states the information is disclosed under market abuse regulation, it functions as a material regulatory disclosure. However, the core purpose is announcing significant new data/results, which often falls under ER if it's periodic, or RNS if it's ad-hoc. Since it's a press release announcing key data points, ER is a strong candidate, but RNS is the safest fallback for material, non-standardized announcements. Given the document is short (under 5000 chars) and functions as a notification of material information disclosure, RNS (Regulatory Filings/General Announcement) is appropriate, although ER is also plausible if this data release is tied to a specific reporting cycle. I will classify it as RNS as it is a general regulatory announcement of clinical data, not strictly an earnings summary.
2019-07-11 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.